Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of the amino acids l-ornithine and l-aspartate, used in the treatment of hyperammonemia associated with liver disease. It is believed to promote ammonia detoxification by stimulating the urea cycle and glutamine synthesis.
## Primary Indications
* Hepatic encephalopathy (in conjunction with standard therapy)
* Hyperammonemia in patients with cirrhosis
## Adult Dosing
* **Intravenous (IV):** 5 g to 10 g (one to two ampules) per 24 hours, infused over 30 to 60 minutes. Dosing and infusion rate may be adjusted based on the patient's response and tolerance.
* **Oral:** Typically 3 to 6 g by mouth per day, divided into 3 doses. The exact oral dosage may vary by formulation and local protocol.
## Pediatric Dosing
* Limited data available for pediatric use. Dosing should be individualized under specialist guidance and based on body weight and clinical response.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is metabolized by the liver and excreted by the kidneys. However, caution is advised in severe renal impairment due to potential accumulation.
## Contraindications
* Known hypersensitivity to l-ornithine l-aspartate.
* Severe renal failure (creatinine > 3 mg/dL).
* Rare genetic metabolic disorders (e.g., urea cycle disorders, unless specifically indicated and monitored).
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal discomfort, flatulence.
* **Less Common:** Dizziness, headache, skin rash, itching.
* **Rare:** Allergic reactions, electrolyte imbalances.
## Key Drug Interactions
* No significant drug interactions have been extensively documented. However, concurrent use with other medications affecting ammonia levels or liver function should be approached with caution.
## Monitoring
* Monitor ammonia levels, liver function tests (LFTs), and clinical signs/symptoms of hepatic encephalopathy.
* Monitor renal function in patients with pre-existing renal impairment.
## Clinical Pearls
* The intravenous formulation is typically used for acute management of hepatic encephalopathy or severe hyperammonemia, while the oral formulation may be used for chronic management.
* It is important to address the underlying cause of hyperammonemia and liver dysfunction in addition to using Hepamerz.
***
*This information is intended for healthcare professionals. Please consult the current prescribing information and relevant clinical guidelines for complete details before use.*
